细胞因子诱导的杀伤细胞治疗恶性黑色素瘤的临床观察  

Effect of autologous cytokine-induced killer cells transfusion on patients with malignant melanoma

作　　者：王子兵[1,2] 张铁寒 尚艺曼[1,2] 刘雨晴[3] 姚毅波[3] 高全立[1,2] 

机构地区：[1]郑州大学附属肿瘤医院 [2]河南省肿瘤医院生物治疗科,河南郑州450008 [3]新乡医学院第三附属医院肿瘤科,河南新乡453003

出　　处：《新乡医学院学报》2013年第11期881-882,886,共3页Journal of Xinxiang Medical University

基　　金：国家自然科学基金青年科学基金项目(编号:81000914);河南省科技攻关计划重大项目(编号:2011010011)

摘　　要：目的比较单纯细胞因子诱导的杀伤细胞(CIK)与单纯化学治疗对晚期恶性黑色素瘤的疗效及不良反应。方法回顾性分析34例恶性黑色素瘤患者的临床资料,其中14例行单纯CIK治疗,20例行单纯化学治疗。观察指标包括客观反应率、疾病控制率、1 a生存率及不良反应。结果 CIK治疗组患者部分缓解2例,病情稳定5例,病情进展7例;客观反应率14.29%,疾病控制率50.00%,1 a生存率57.14%。化学治疗组患者部分缓解3例,病情稳定8例,病情进展9例;客观反应率15.00%,疾病控制率55.00%,1 a生存率40.00%。2组患者客观反应率、疾病控制率和1 a生存率比较差异均无统计学意义(P>0.05),但CIK治疗组不良反应发生率显著低于化学治疗组(P<0.05)。结论 CIK治疗晚期恶性黑色素瘤与化学治疗疗效相当,但不良反应轻微,可作为治疗选择之一。Objective To compare the efficacy and side effects of cytokine-induced killer cells （CIK） therapy and chemotherapy in advanced malignant melanoma. Methods The clinical data of thirty-four patients with advanced malignant melanoma were analyzed retrospectively. Fourteen cases were treated by CIK therapy and twenty cases by chemotherapy. Objec- tive response rate, disease control rate, one-year survival and side effects were observed. Results In CIK therapy group, objec- tive response rate was 14. 29%, disease control rate was 50.00%, with 2 cases of partial remission （PR） ,5 cases of stable dis- ease （SD） and 7 cases of progressive disease （PD） ;the 1-year survival rate was 57.14%. In chemotherapy group, objective re- sponse was 15.00% , disease control rate was 55.00% , with 3 cases of PR,8 cases of SD and 9 cases of PD;the 1-year survival rate was 40.00%. There was no statistical significance in objective response rate, disease control rate and 1-year survival rate between the two groups（P 〉0.05）. But the side effect incidence in CIK therapy group was lower than that in chemotherapy group（ P 〈 0.05 ）. Conclusion The therapeutic effect of CIK therapy and chemotherapy is equivalent, but the side effect of CIK therapy is little,it can be chosen as one type of therapies in advanced malignant melanoma patients.

关 键 词：恶性黑色素瘤 细胞因子诱导的杀伤细胞 免疫治疗 

分 类 号：R739.5[医药卫生—肿瘤]